4.7 Review

MicroRNAs, Multiple Sclerosis, and Depression

Journal

Publisher

MDPI
DOI: 10.3390/ijms22157802

Keywords

biomarker; depression; microRNA; multiple sclerosis; treatment

Funding

  1. Ministry of Science and Technology [107-2118-M-009-002MY2]

Ask authors/readers for more resources

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system, with up to 50% of patients experiencing depressive disorders. Major depression (MD) is a serious comorbidity of MS, potentially involving various dysfunctions.
Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects the brain and spinal cord. There are several disease courses in MS including relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). Up to 50% of MS patients experience depressive disorders. Major depression (MD) is a serious comorbidity of MS. Many dysfunctions including neuroinflammation, peripheral inflammation, gut dysbiosis, chronic oxidative and nitrosative stress, and neuroendocrine and mitochondrial abnormalities may contribute to the comorbidity between MS and MD. In addition to these actions, medical treatment and microRNA (miRNA) regulation may also be involved in the mechanisms of the comorbidity between MS and MD. In the study, I review many common miRNA biomarkers for both diseases. These common miRNA biomarkers may help further explore the association between MS and MD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available